Lifecore Biomedical, Inc.
LFCR · NASDAQ
5/25/2025 | 5/26/2024 | 5/28/2023 | 5/29/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 0.5% | 24.2% | -7.2% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 31.3% | 32.6% | 27.1% | 35.1% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -13.4% | -6.9% | -21.1% | -10.6% |
| Other Income/Exp. Net | -$0 | $0 | -$0 | -$0 |
| Pre-Tax Income | -$0 | $0 | -$0 | -$0 |
| Tax Expense | $0 | $0 | $0 | -$0 |
| Net Income | -$0 | $0 | -$0 | -$0 |
| % Margin | -30% | 9.4% | -96.4% | -104.9% |
| EPS | -1.27 | 0.39 | -3.32 | -3.97 |
| % Growth | -425.6% | 111.7% | 16.4% | – |
| EPS Diluted | -1.27 | 0.33 | -3.32 | -3.97 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | $0 | -$0 | $0 |
| % Margin | -6.8% | 27.8% | -32.1% | 11.5% |